Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Thermo Fisher Scientific to bring biomarker assays to Alere platform

Thermo Fisher Scientific to bring biomarker assays to Alere platform

26th July 2011

Thermo Fisher Scientific will be bringing its Brahms biomarker assays to the Triage point-of-care platform, created by Alere.

The firm has signed a long-term license agreement with the point-of-care diagnostics specialist to make biomarkers such as the Brahms Procalcitonin test – used in the detection of sepsis – available for the system.

As part of the deal, Alere will also be adapting biomarkers such as the Brahms Copeptin, MR-proADM and MR-proANP for Triage, thus making them accessible to a much wider patient population.

Thermo Fisher Scientific has expressed confidence that this alliance will help to improve patient care quality in hospitals and healthcare facilities.

Marc Casper, president and chief executive officer of Thermo Fisher Scientific, said: "Improving patient care while reducing the cost of diagnosing disease will provide a much needed boost to hospitals struggling to maintain service levels and remain competitive."

Last week, the organisation agreed a deal to purchase Trek Diagnostic Systems, a microbiology solutions provider currently owned by Magellan Biosciences.ADNFCR-8000103-ID-800634265-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.